Clonidine is a preferential alpha-2 agonist drug that has been used for over 35 years to treat hypertension. Recently, it has also been used as a preoperative medication and as a sedative/anxiolytic drug. This randomized, double-blind, placebo-controlled crossover clinical trial characterized the effects of oral clonidine pretreatment on intravenous catheter placement in 13 patients. Parameters measured included the bispectral index (BIS), Observer's Assessment of Alertness/Sedation Scale (OAA/S), frontal temporal electromyogram (EMG), 30-Second Blink Count (Blink), Digit Symbol Substitution Test (DSST), State Anxiety Inventory (SAI), fingertip versus forearm skin temperatures, and multiple questionnaires. Oral clonidine significantly decreased SAI scores, OAA/S, EMG, and Blink, but did not cause statistically significant BIS or DSST reductions. Subjects preferred oral clonidine pretreatment prior to venipuncture compared to placebo. Questionnaires also indicated that clonidine provided minimal sedation, considerable anxiolysis, and some analgesia. Fingertip versus forearm skin temperature differentials were decreased. Reduced fingertip versus forearm temperature differentials suggest increased peripheral cutaneous blood flow prior to venous cannulation. Oral clonidine pretreatment not only helped control patient anxiety and pain but also provided cardiovascular stability.
I ntravenous (IV) catheters have become the accepted standard of care for general anesthesia and IV sedation. 1 Catheterization of peripheral veins can be made more comfortable using a variety of techniques, including local anesthesia infiltration, 2,3 nitrous oxide inhalation, 2, 4, 5 ethyl chloride topical, 4,6 eutectic mixture of local anesthetics (lidocaine-prilocaine) cream, 7,8 tetracaine patches, 9 and even midazolam nasal spray. 10 The goals of these methods are pain and anxiety reduction with minimal invasiveness and lack of significant complications. An additional benefit of some cannulation pretreatments is cutaneous vasodilation.
Previous medical anesthesia/sedation studies have indicated that clonidine administration prior to surgery decreases pain 11, 12 and anxiety 12 and also stabilizes blood pressure and heart rate by reduction of central sympathetic outflow. [13] [14] [15] Additional investigations have shown that clonidine pretreatment also increases skin temperature 16 and decreases the difference between fingertip and forearm temperatures. 17 These results suggest an increase in cutaneous blood flow. 18 The purpose of this randomized, double-blind, placebo-controlled crossover clinical trial was to characterize the sedative/anxiolytic effects and changes in skin temperatures of oral clonidine pretreatment prior to IV catheter placement.
METHODS
The study protocol and informed consent form were approved by The Ohio State University Institutional Review Board. Inclusion criteria were (a) adults with American Society of Anesthesiologists ASA1 or ASA2 health status, (b) severe chronic periodontal disease and/or the 19 Each subject took nothing by mouth for 8-12 hours and was accompanied and transported by a responsible adult. All subjects arrived 1 hour prior to scheduled periodontal surgery (time ϭ 0) and were seated in a semisupine position in a standard dental chair. Baseline skin temperatures (T1, finger, and T2, forearm), BIS ( Figure  1 ), Observer's Assessment of Alertness/Sedation Scale (OAA/S; Table 1 ), frontal temporal electromyography (EMG), 30-Second Blink Count (Blink), Digit Symbol Substitution Test (DSST), and Spielberger State Anxiety Inventory Scores (SAI) were recorded. The DSST asks subjects to decode, digit-associate, and write as many simple geometric symbols as possible within 90 seconds. The DSST was initially administered 2-4 times to minimize learning effects, and the final score was recorded. The SAI is a 20-question inventory with responses rated on a 1 to 4 scale. SAI scores range from 20 (low anxiety state) to 80 (high anxiety state). Subjects were also shown a photograph of a simple object for 5 seconds to remember. Each patient then swallowed 1 capsule of clonidine (0.1 mg/35 kg body weight) or 1 placebo capsule. An Aspect A-1050 BIS monitor (As- pect Medical Systems, Newton, Mass) was used with default settings including a 30-second smoothing time. A standard frontal temporal montage was recorded using BIS sensor electrodes applied to the scalp-left temple after mild cotton 2 ϫ 2 abrasion resulting in contact impedance under 5 k⍀. Frontal temporal EMG logarithmic decibel values were rounded to the nearest 5 db (30, 35, 40, 45, 50, 55, 60, 65, or 70) . Immediate access to the blinded list of drug assignments was available in case of emergency.
One hour after oral premedication with clonidine or placebo (time ϭ 60), all baseline measurements were repeated. A 20-gauge, 2.54-cm (1-in) Jelco (Ethicon Inc., Arlington, Tex) intravenous catheter was then placed in each subject's arm or hand. IV lines were maintained with 5% dextrose and normal saline at a rate of 100 mL/h. The same sedationist performed intravenous cannulation for each patient at both of the patient's sessions using identical techniques. A corresponding site on the same or opposite arm or hand was catheterized at the second session. During all sessions, talking and background noise were minimized because patients sedated with clonidine are easy to arouse. 20 Patients were encouraged to use restroom facilities prior to sedation sessions because clonidine can exert a mild diuretic effect. 21 Patients breathed 4 L/min of 100% O 2 via nasal cannula during venipuncture.
Recall and recognition were tested following at least 2 hours of intravenous conscious sedation and approximately 20 minutes of recovery (time ϭ 200) via a postsession follow-up questionnaire and all original baseline measurements repeated. The sedationist and surgeon also completed postsession questionnaires. All subjects also completed a poststudy questionnaire immediately following the second session ( Figure 2 ). Although the study design included evaluation of vital signs and responses during sedation, the present report is limited to the effects of clonidine administration on venipuncture.
Quantitative changes in BIS were compared using a Friedman test with P Յ .05 considered significant. Parametric data including fingertip and forearm skin temperatures were analyzed using paired and unpaired 2tailed t tests with ͦtͦ Ͻ 0.05 significant. Each subject participated in 2 test sessions in randomized order with clonidine (clonidine sessions) and with placebo (control sessions) and acted as his or her own control. Postsession and poststudy questionnaires along with amnesia results were assessed and validated by comparison to a previous study 19 including nonsedated controls. Questionnaire and amnesia results were also correlated with objective data from this study (OAA/S, BIS, EMG, SAI, Blink, and DSST). Simple yes/no memory percentage correct amnesia data and survey responses were evaluated by chi-square likelihood ratios, with P Յ .05 considered significant. OAA/S, EMG, Blink, DSST, SAI, and survey score differences were analyzed using paired 2-tailed t tests (ͦtͦ Յ 0.05 considered significant) or Wilcoxon signed-rank tests (ͦzͦ Յ 0.05 considered significant).
RESULTS
Three of 16 subjects did not complete their second sessions. A statistically significant majority of subjects (9) preferred clonidine pretreatment prior to venipuncture over intravenous cannulation with placebo (P Ͻ .05). Four subjects expressed no preference and no subject favored placebo pretreatment. No statistically significant correlations were observed between the order of the 2 sessions, venipuncture site, surgical procedure(s) performed, surgeon, sedationist (venipuncturist), date and time of treatment, and any other variables measured in this study. Tables 2 and 3 list fingertip versus forearm skin temperatures before (time ϭ 0) and 1 hour after (time ϭ 60) pretreatment with clonidine (Table 3 ) versus placebo ( Table 2) . Fingertip skin temperatures after clonidine pretreatment were elevated significantly compared to pretreatment baselines (ͦtͦ Ͻ 0.05). Differences between forearm and fingertip temperatures in individual subjects were significantly decreased by clonidine pretreatment (ͦtͦ Ͻ 0.05). Tables 4 and 5 show BIS, OAA/S, EMG, DSST, SAI, and Blink values before (time ϭ 0) and 1 hour after (time ϭ 60) oral clonidine (Table 5 ) and placebo administration (Table 4 ). Clonidine pretreatment significantly reduced OAA/S, EMG, SAI, and Blink (P Ͻ .05) at time ϭ 60 compared to time ϭ 0. DSST results did not detect significant impairment compared to baseline after oral clonidine (time ϭ 60). BIS readings were reduced following clonidine administration, but the reductions were not statistically significant. Table 6 summarizes surgeon, sedationist, and subject responses to questionnaires. All 3 respondents favored clonidine over placebo, but the results were statistically significant for subjects only. Table 7 lists amnesia results for clonidine and placebo groups. All subjects remembered intravenous catheterization both with clonidine and with placebo pretreatment. Oral clonidine pretreatment did not significantly change picture memory percentage correct.
No study subject experienced or reported any untoward reactions or complications including rebound hypertension from oral clonidine. No subject required emergency treatment. One subject did go through a brief syncopal episode during venipuncture after placebo pretreatment. This episode was preceded by a drop in BIS below 70. There was no significant difference in the number of subjects needing to urinate during study sessions with clonidine or with placebo. The ''blinded list of drug assignments'' were not revealed until the study was completed.
DISCUSSION
Clonidine (Catapres), an imidazoline compound, was introduced 35 years ago, first as a treatment for nasal congestion and then for hypertension. [22] [23] [24] Clonidine has also been used to treat and/or prevent diarrhea, 25 manic and bipolar symptoms, 26 muscle rigidity and spas-ticity, 27 hyperactivity and attention deficit disorder in children, 28 withdrawal states, 29-32 congestive heart failure, 33 new-onset rapid atrial fibrillation, 34 angina pectoris, 35 myocardial infarction, 36 post-general anesthesia shivering 37 and agitation, 38-41 glaucoma, 42 chronic pain, 43 and syncope. 44 It can also supplement peribulbar, 45 epidural, 46 and intrathecal anesthesia. 47 Recently, clonidine has been utilized as a preoperative medication providing anxiolysis, 12,48 sedation, 49 analgesia, 11, 50, 51 hemodynamic stability, 13,50-53 saliva control, 23, 54 and antiemetic effects. 55 It also possesses sedative-, 56, 57 anesthetic-, 58, 59 and analgesic-sparing 13, 53 properties. Clonidine exhibits anxiolytic effects independent of sedation 60 and also reduces perioperative plasma catecholamine 53 and prolactin 61 concentrations. Optimal oral premedication dosage has been established at 0.2 mg for an average 70-kg adult. 62 Clonidine is a relatively nontoxic drug, as indicated by case reports of 50-to 1000-fold overdoses resulting in no permanent injuries. [63] [64] [65] [66] A single 0.2-mg dose of clonidine exhibits its maximal hypotensive effect 60-90 minutes after oral administration. Single doses do not cause rebound hypertensive effects occasionally associated with discontinuation of long-term treatment. When used as an oral premedication, clonidine rarely causes significant bradycardia and/or hypotension requiring treatment with IV fluids, atropine, or other medications. 49, 67, 68 The small decreases in heart rate and in systolic, diastolic, and mean ar- terial blood pressures following oral clonidine administration generally have no harmful clinical consequences and cause no clinical symptoms or apparent problems. These findings are confirmed and reinforced by a large body of literature. 12, 13, 15, [49] [50] [51] [52] [53] [55] [56] [57] [58] 67, 69, 70 Clonidine is a mixed alpha agonist drug possessing peripheral ␣1 and ␣2 activity as well as imidazoline agonist effects. In low doses it primarily produces central ␣2 effects. 70 Clonidine exhibits an ␣2 : ␣1 selectivity ratio of 200 : 1 and an ␣2a to imidazoline activity ratio of 16. 71 Even though various ␣2 antagonists, including atipamezole, have experimentally reversed clonidine in humans, they are currently approved for veterinary applications only. 72
The results of this study are consistent with the known properties of clonidine. Clonidine-induced anxiolysis prior to venipuncture was indicated by statistically significant 13% reductions in SAI and validated by subject surveys. The SAI has been utilized for decades in countless studies and recently has been used to evaluate the anxiolytic properties of clonidine. 48, [73] [74] [75] Significant decreases in OAA/S and EMG values at time 60 after clonidine administration indicated mild sedation. Statistically insignificant decreases in BIS were also observed 1 hour after oral clonidine administration ( Table 5 ). Malinovsky et al 76 reported small but statistically significant BIS depression following large doses of intrathecal clo- nidine. Recent studies have used BIS to evaluate dental sedation. 19, 77 DSST is a measure of cognitive and psychomotor impairment that has been used to evaluate recovery from various sedation agents. 78, 79 Blink counts have also been utilized to assess sedation, impairment, and recovery. 80-82 Both Blink and DSST measurements decrease during sedation and return to normal baselines after recovery. Significant decreases in Blink were seen 1 hour after clonidine pretreatment versus placebo. DSST results in this study did not detect significant impairment because of clonidine pretreatment at time 60 compared to time 0.
Nine of 13 (69%) of subjects reported that oral clonidine pretreatment reduced discomfort of intravenous catheter placement compared to pretreatment with placebo (P Ͻ .05). Clonidine also significantly reduced fingertip versus forearm skin temperature differentials, suggesting an increase in cutaneous blood flow. This could be an additional advantage to enable easier intravenous access, especially when anxious patients exhibit high sympathetic tone and increased peripheral vascular constriction. One subject experienced a brief syncopal episode preceded by a significant drop in BIS 83 during venipuncture with placebo pretreatment. This subject did not faint during catheter placement with clonidine pretreatment.
The limitations of this study include the relatively low number of subjects (N ϭ 13), the difficulty in maintaining blinding because of obvious signs after clonidine administration in some patients, and the inherent difficulties in making subjective evaluations of sedation levels. 84 Although oral clonidine pretreatment seems to be purely beneficial, negative effects, including prolonged recov-ery, hypotension, and bradycardia could be discovered with further investigations and larger sample sizes. The next generation of more potent, more receptor-specific central ␣2 agonists such as dexmedetomidine 43, 71, 85 is already available in the United States. Perhaps increased utilization of ␣2 drugs will lead to FDA approval of atipamezole as a reversal agent. 72 The apparent advantages of oral clonidine prior to venipuncture may also be of value in oral sedation 86 of mildly anxious patients prior to routine dental injections and minor dental procedures. Additional research is needed, especially for possible benefits to dental patients who are hypertensive and/or exhibit cardiovascular instability.
